Aug 12, 2020
PDL BioPharma Enters Into Settlement Agreement with Wellstat
May 18, 2020
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
Apr 30, 2020
PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020
Feb 28, 2020
PDL BioPharma Enters into Cooperation Agreement with Engine Capital
Dec 19, 2019
PDL BioPharma Announces Upcoming Changes to its Board of Directors
Dec 16, 2019
PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million
Dec 13, 2019
PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024
Nov 14, 2019
PDL BioPharma Reaffirms Commitment To Shareholder Value Creation
Oct 24, 2019
PDL BioPharma Responds to Letter from Engine Capital
Jul 31, 2019
PDL BioPharma to Announce Second Quarter 2019 Financial Results on August 7, 2019
Jun 25, 2019
PDL BioPharma Announces Departure of CFO
Jun 24, 2019
Natasha A. Hernday Elected to PDL BioPharma's Board of Directors
May 02, 2019
PDL BioPharma to Announce First Quarter 2019 Financial Results on May 9, 2019
Apr 11, 2019
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
Oct 31, 2018
PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018
Oct 08, 2018
PDL BioPharma Names Edward Imbrogno Vice President of Finance
Sep 26, 2018
PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
Aug 30, 2018
PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Aug 02, 2018
PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products
Jun 22, 2018
Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors